Literature DB >> 31353436

Ellagic Acid Enhances Antitumor Efficacy of Temozolomide in an in vitro Glioblastoma Model.

Abdurrahman Cetin1, Burcu Biltekin.   

Abstract

AIM: To observe the effect of combining ellagic acid (EA), a natural phenol present in fruits and vegetables, and temozolomide (TMZ) on the proliferation and expression profile of C6 glioma cell line.
MATERIAL AND METHODS: Rat C6 glioma cells were treated with 100-?M EA combined with 100 ?M TMZ for 24, 48, and 72 hours (h). Cell proliferation and p53 and caspase-3 protein levels were evaluated using immunocytochemistry. Multi drug resistance 1 (MDR1), O6-methylguanine-DNA methyltransferase (MGMT), and apoptotic protein (caspase-3 and p53) expressions were assessed using reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: EA combined with TMZ conspicuously reduced the cell viability at all incubation times (p < 0.001). EA significantly downregulated MGMT expression regardless of the presence of TMZ even at early hours (p < 0.001). The combination therapy reduced MDR1 expression only on 48 h in comparison with TMZ alone. EA alone upregulated caspase-3 at 48 h but upregulated p53 at 48 and 72 h. The combined therapy enhanced the immunoreactivities of p53 and caspase-3 proteins independent of the treatment durations but not of the genes.
CONCLUSION: EA combined with TMZ may have a potential antiproliferative efficacy by inhibiting MGMT expression and activating apoptotic protein, p53 and caspase-3, expression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31353436     DOI: 10.5137/1019-5149.JTN.26026-19.1

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  2 in total

1.  Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.

Authors:  Abdurrahman Cetin; Burcu Biltekin; Huseyin Ozevren
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-07       Impact factor: 1.712

Review 2.  Advances in Dietary Phenolic Compounds to Improve Chemosensitivity of Anticancer Drugs.

Authors:  Abdelhakim Bouyahya; Nasreddine El Omari; Saad Bakrim; Naoufal El Hachlafi; Abdelaali Balahbib; Polrat Wilairatana; Mohammad S Mubarak
Journal:  Cancers (Basel)       Date:  2022-09-21       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.